This Should be a Very Interesting Session at Cell & Gene Therapy World, January 27, 2016

Holmes v Gregory Mano a Mano

Focus Session 1

Genome editing: How do the major platforms compare in both in vivo and ex vivo settings?

11:45 - 11:50

Chair's introduction

• Dr Stephen MingerDirectorSLM Blue Skies Innovations, Ltd

11:50 - 12:10

Industry case study 1: ZFNs

• Dr Michael HolmesVice President, ResearchSangamo BioSciences, Inc

12:10 - 12:30

Industry case study 2: CRISPR

• Dr Alexandra GlucksmannChief Operating OfficerEditas Medicine

12:30 - 12:50

Industry case study 3

TALEN®-based targeted genome modifications for improved CAR T-cell adoptive immunotherapy

• Dr Alexandre JuilleratSenior ScientistCellectis

12:50 - 13:10

Industry case study 4: Homing Endonuclease and MegaTAL

• Dr Philip D. GregoryChief Scientific Officerbluebird bio